ClinicalTrials.gg
RecruitingNCT06273059Updated Feb 22, 2024

Genomic Study of Young-Onset Diabetes Mellitus

An observational study in Genomic, Diabetes Mellitus and MODY, sponsored by Indonesia University. Recruiting at 1 site in Indonesia. Open to participants aged 8 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-22.

Sponsored by Indonesia University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000
Ages
8 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Diabetes Mellitus with a site in Indonesia — 7 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus · Indonesia.

Planned enrollment
11th of 17
1,000 · median 1,584
Started
2022
with 2 others
Observational
17 of 46
3 open now
Registered
32nd of 46
by date
Lead sponsor
7 of 46
Indonesia University

Among the 46 studies in Diabetes Mellitus with a site in Indonesia, this one is the 11th largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2022, is one of 17 observational ones, and was the 32nd registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

7 of the 46 studies in Diabetes Mellitus with a site in Indonesia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 8 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Diabetes Mellitus with a site in Indonesia, or all of them as a file.
02

Study summary

Diabetes Mellitus (DM) has been a major contributor to health burden in Indonesia and currently its burden still continues to rise. This is a result of increasing DM prevalence in the country as well as high rates of chronic complications from DM. Findings in Indonesia show that there is a high proportion of young people with diabetes, and also a high risk of therapeutic failure and complications from DM occurring in the younger population.

Young-onset DM has a wide clinical spectrum, including autoimmune DM, polygenic DM, and monogenic DM such as Mature Onset Diabetes of the Young (MODY). Identification and proper diagnosis of young-onset DM spectrum is crucial to treatment outcomes, as certain spectrums, such as some subtypes of MODY, may benefit from cost-efficient alternatives with better outcomes.

However, proper diagnosis of young-onset DM in Indonesia is still a great challenge, as currently some examinations, including genetic testing, has not yet been feasibly done in the country. With current advances in genomics, genetic testing may prove to be fundamental in providing optimal and personalized treatment and care for DM patients.

This study is a pilot project aimed to initiate genomic research in young-onset DM patients in Indonesia. In the short term, this study aims to identify genetic variants that may be able to increase diagnostic accuracy of the young-onset DM spectrum. In the long term, this study aims to identify new genetic variants of young-onset DM. The study also aims to identify genetic variants associated with risks of chronic complications.

Read the detailed description

Type 2 diabetes mellitus (T2DM) is a progressive, degenerative chronic disease which clinically manifests as hyperglycemia due to resistance and/or insulin deficiency.(1) According to data from the International Diabetes Federation (IDF), in 2017, around 425 million people in the world have diabetes, and it is predicted that this figure would increase up to 629 million by 2045.(2) Currently, diabetes has become a major contributor to health burden and its prevalence has been steadily increasing. Indonesia places sixth among countries with the highest number of people with diabetes with around 10.3 million in 2017(2) which then increase to more than 19 million in 2021. This is aligned with an increase in diabetes mellitus (DM) prevalence in Indonesia from 5,6% in 2007 to 10,9% in 2018. (3,4) The high prevalence of DM in Indonesia causes great burden in its health sector, both directly and indirectly. Most of the burden brought by DMT2 is contributed by various possible complications as the disease progresses. (1) Chronic complications of DMT2 comprises of vascular disorders, both microangiopathy or macroangiopathy, metabolic disorders and increased risk of infection. (5) Microangiopathy complications include retinopathy which may lead to blindness, nephropathy which may lead to kidney failure, peripheral neuropathy which may severely affect quality of life and diabetic cardiopathy which may lead to heart failure. Macroangiopathy complications include coronary heart disease, stroke, and peripheral artery disease (PAD) which may lead to amputation. (5) Other complications include increased risk of liver cirrhosis due to fatty liver, sexual dysfunction, and increased risk of certain infections such as tuberculosis (TB). (6-8) DM is also associated with higher risk of mortality from COVID-19.

Several studies show that the rate of complications from DM is quite high. According to a study from Dr. Cipto Mangunkusumo National General Hospital in 2011, neuropathy is found to be the most frequent complication (54%), followed by retinopathy (33.4%) and proteinuria (26.5%). (9,10) Two major factors which contribute to these frequent rates of complications are late diagnosis and poor glycemic control. Another finding which may also contribute to this phenomenon is that there is a high proportion of young people with diabetes in Indonesia, whereby studies show that DM in young people has higher risks of therapeutic failure and chronic complications. (11, 12) The high rates of therapeutic failure and chronic complications in people with young-onset DM may greatly affect not only directly through financial burden from healthcare, but also indirectly through arising problems in daily life such as decreased productivity. Diabetics with chronic complication may spend more time in healthcare facilities rather than in other activities, compromising work productivity. Hence, a sufficient understanding of risk factors and clinical spectrums of young-onset DM is important for providing optimal care.

Ethnicity and intrauterine environment might be strong predictors of young-onset T2DM. (11) Obesity, history of low birth weight, and genetic factors also contribute significant roles. (11) The clinical spectrum of young-onset DM varies, including autoimmune DM, polygenic DM, and monogenic DM such as Mature Onset Diabetes of the Young (MODY). Accurate diagnosis plays an important role in providing proper treatment to prevent chronic complications.

MODY is a monogenic form of diabetes in the form of autosomal dominant non-insulin dependent diabetes. (13) MODY contributes to 1-5% of DM cases and symptoms generally appear at a young age (\<25 years old). MODY is commonly misdiagnosed as type 1 DM (T1DM) or T2DM. Molecular diagnosis is needed for the accurate diagnosis and optimal treatment of MODY. It also provides possible means to screen and provide early diagnosis of asymptomatic family members. (13) Some subtypes of MODY (HNF1A, HNF4A, KCNJ11, dan ABCC8) may optimally be treated with sulfonylureas, which would be more cost-efficient and provide better clinical outcomes compared to insulin therapy. However, this has not been feasible in Indonesia as some examinations, especially genetic testing, may only be performed by sending samples overseas which would cost greatly. This has proved to be an obstacle to providing tailored or personalized therapy for patients. Personalised medicine involves not only giving accurate diagnosis, but also providing proper choice of therapy as well as predicting possible complications that may appear so that intervention may be done early in their course. To achieve this, genetic testing might be fundamental. In the present, genomic testing in DM is rapidly and continuously developing. This study aims to initiate genomic research in young-onset DM patients in Indonesia. In the short term, this study aims to identify genetic variants that may be able to increase diagnostic accuracy of the young-onset DM spectrum. This may also serve as a baseline for providing personalised medicine care. In the long term, this study aims to identify new genetic variants of young-onset DM.

RESEARCH OBJECTIVES The overall objective of this study is to identify and describe genetic variation of young-onset DM in Indonesia.

The specific objectives are:

  1. To describe the proportion of MODY in young-onset DM.
  2. To describe genetic variation of MODY in Indonesia.
  3. To describe genetic variation in young-onset DM with diabetic complications in various systems:

    1. Cardiovascular complications: coronary heart disease (CHD) and diabetic cardiomyopathy
    2. Peripheral vascular complications
    3. Neurological complications: cerebrovascular disease (CVD) and peripheral neuropathy
    4. Diabetic nephropathy
    5. Diabetic retinopathy
    6. Fatty liver and fatty pancreas
    7. Hearing impairment
    8. Sexual dysfunction

Study Population and Sample The study population is early-onset DM patients. Subjects will be recruited from outpatient clinics Dr. Cipto Mangunkusumo National General Hospital metabolic and endocrine outpatient clinic and KIARA pediatric endocrine outpatient clinic from September 2022 to April 2024. The study will also recruit healthy controls who fulfill the inclusion criteria. Healthy controls will be recruited from Dr. Cipto Mangunkusumo National General Hospital employees undergoing medical checkups and the general population if target sample size has not been met. The study aims to recruit 1,000 diabetic patients and 1,000 healthy controls.

Diabetic patients Inclusion criteria

  • Diabetic patient fulfilling criteria from Indonesian Endocrinology Association (PERKENI) 2021 guidelines:

    • Fasting blood glucose 126 mg/dL
    • 2-hour post oral glucose blood glucose/oral glucose tolerance test 200 mg/dL
    • HbA1c 6.5%
    • Random blood glucose 200 mg/dL with classic symptoms or hyperglycemic crisis.
  • Patients aged 8-40 years old when diagnosed with diabetes mellitus
  • Registered in Dr. Cipto Mangunkusumo National General Hospital and satellite hospitals
  • Willing to participate in the study with proof of informed consent agreement Exclusion criteria
  • Subject is experiencing severe illness

Healthy controls Inclusion criteria

  • Aged 8-40 years old
  • Fulfilling criteria of normal blood glucose levels according to Indonesian Endocrinology Association (PERKENI) 2021 guidelines:

    • Fasting blood glucose 100 mg/dL
    • 2-hour post oral glucose blood glucose/oral glucose tolerance test 140 mg/dL
    • HbA1c 5.7% Exclusion criteria
  • Subject is unwilling to participate in the study
03

Conditions studied

  • Genomic
  • Diabetes Mellitus
  • MODY

Keywords

  • Genomic
  • Diabetes mellitus
  • MODY
04

Who can participate

Ages eligible
8 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population is early-onset DM patients. Subjects will be recruited from outpatient clinics Dr. Cipto Mangunkusumo National General Hospital metabolic and endocrine outpatient clinic and KIARA pediatric endocrine outpatient clinic from September 2022 to April 2024. The study will also recruit healthy controls who fulfill the inclusion criteria. Healthy controls will be recruited from Dr. Cipto Mangunkusumo National General Hospital employees undergoing medical checkups and the general population if target sample size has not been met. The study aims to recruit 1,000 diabetic patients and 1,000 healthy controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetic patients

    • Diabetic patient fulfilling criteria from Indonesian Endocrinology Association (PERKENI) 2021 guidelines:

      • Fasting blood glucose 126 mg/dL
      • 2-hour post oral glucose blood glucose/oral glucose tolerance test 200 mg/dL
      • 6.5%
      • Random blood glucose 200 mg/dL with classic symptoms or hyperglycemic crisis.
    • Patients aged 8-40 years old when diagnosed with diabetes mellitus
    • Registered in Dr. Cipto Mangunkusumo National General Hospital and satellite hospitals
    • Willing to participate in the study with proof of agreement

Exclusion criteria

Exclusion Criteria:

  • Subject is experiencing severe illness

Healthy controls Inclusion criteria

  • Aged 8-40 years old
  • Fulfilling criteria of normal blood glucose levels according to Indonesian Endocrinology Association (PERKENI) 2021 guidelines:

    • Fasting blood glucose 100 mg/dL
    • 2-hour post oral glucose blood glucose/oral glucose tolerance test 140 mg/dL
    • 5.7% Exclusion criteria
  • Subject is unwilling to participate in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Diabetic patients and Healthy controls

    Diabetic patients and Healthy controls

06

What researchers measure

Primary outcomes

  1. The overall objective of this study is to identify and describe genetic variation of young-onset DM in Indonesia.

    Time frame: 1 years

Secondary outcomes

  1. To describe the proportion of MODY in young-onset DM

    Time frame: 1 years

  2. To describe genetic variation of MODY in Indonesia.

    Time frame: 1 years

  3. To describe genetic variation in young-onset DM with diabetic complications in various systems:

    Cardiovascular complications: coronary heart disease (CHD) and diabetic cardiomyopathy b. Peripheral vascular complications c. Neurological complications: cerebrovascular disease (CVD) and peripheral neuropathy d. Diabetic nephropathy e. Diabetic retinopathy f. Fatty liver and fatty pancreas g. Hearing impairment h. Sexual dysfunction

    Time frame: 1 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Dec 2024, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Feb 22, 2024
StartActual
Sep 12, 2022
Primary completionEst.
Dec 12, 2024
CompletionEst.
Dec 12, 2024
Last update
Feb 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06273059
Responsible party
Dicky L Tahapary (Dr, Indonesia University) — Principal investigator
First posted
Feb 22, 2024
Start date
Sep 12, 2022
Primary completion
Dec 12, 2024 (estimated)
Completion
Dec 12, 2024 (estimated)
Last update
Feb 22, 2024

Study contacts

Dicky Tahapary
Contact
penelitian.endokrin@gmail.com
+6213907703
Dicky Tahapary
Contact
dicky.tahapary@ui.ac.id
Dicky Tahapary
principal investigator · Indonesia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion